687 results on '"Lund, Lars H."'
Search Results
2. Epigenetic modulators link mitochondrial redox homeostasis to cardiac function in a sex-dependent manner
3. Generalizable Approach to Quantifying Guideline-Directed Medical Therapy
4. Preemptive Versus Urgent Heart Failure Hospitalization as a Surrogate for Mortality Risk in Heart Failure
5. Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies
6. Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction – a secondary analysis of TOPCAT
7. Does Heterogeneity Exist in Treatment Associations With Renin–Angiotensin–System Inhibitors or Beta-blockers According to Phenotype Clusters in Heart Failure with Preserved Ejection Fraction?
8. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic
9. Heart failure registries – Future directions
10. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure
11. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
12. Clinical Features of Heart Failure With Normal Ejection Fraction: Insights From the ASIAN-HF Registry
13. Changing health related quality of life and outcomes in heart failure by age, sex and subtype
14. Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF
15. Identifying distinct clinical clusters in heart failure with mildly reduced ejection fraction
16. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
17. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
18. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
19. Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF
20. Impact of progressive aortic regurgitation on outcomes after left ventricular assist device implantation
21. Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study
22. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
23. Associations between rheumatoid arthritis, incident heart failure, and left ventricular ejection fraction
24. A machine learning model for prediction of 30-day primary graft failure after heart transplantation
25. Heart Failure Drug Treatment—Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)
26. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry
27. From mid-range to mildly reduced ejection fraction heart failure: A call to treat
28. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat
29. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
30. Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry
31. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT‐HFpEF): Rationale and design.
32. Heart failure in Europe: Guideline‐directed medical therapy use and decision making in chronic and acute, pre‐existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction – the ESC EORP Heart Failure III Registry.
33. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis.
34. Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial.
35. Association Between β-Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry
36. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial
37. Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF
38. Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry
39. Accuracy of echocardiographic estimates of pulmonary artery pressures in pulmonary hypertension: insights from the KARUM hemodynamic database
40. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe
41. The Differential Impact of the Left Atrial Pressure Components on Pulmonary Arterial Compliance–Resistance Relationship in Heart Failure
42. Heart Failure in Patients Undergoing Elective and Emergency Noncardiac Surgery: Still a Poorly Addressed Risk Factor
43. Pronóstico al año en pacientes con insuficiencia cardiaca en España. Registro ESC-EORP-HFA Heart Failure Long-Term
44. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC.
45. Eligibility for omecamtiv mecarbil in a real-world heart failure population: Data from the Swedish Heart Failure Registry.
46. Sex differences in the prognostic role of achieving target doses of heart failure medications: Data from the Swedish Heart Failure Registry.
47. Cause‐specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry.
48. N‐terminal pro‐B‐type natriuretic peptide concentrations, testing and associations with worsening heart failure events.
49. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: Data from the Swedish Heart Failure Registry.
50. Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.